GALECTO INC (GLTO)
US36322Q1076 - Common Stock
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
An NCI-supported Phase 2 investigator-initiated trial at the Providence Cancer Institute in Portland, Oregon, has enrolled its first patient in a study...
GLTO Stock Earnings: Galecto Beats EPS for Q4 2023
GLTO stock results show that Galecto beat analyst estimates for earnings per share the fourth quarter of 2023.
GLTO Stock Earnings: Galecto Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Galecto (NASDAQ:GLTO) just reported results for the fourth quarter of 2023.Gale...
Galecto stock rallies 25% on positive data for myelofibrosis drug (GLTO)
Galecto (GLTO) stock rallied 25% in post-market trading Thursday on positive Phase 2 data for the company's myelofibrosis drug. Read more here.
Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis
Six of ten evaluable myelofibrosis patients who received GB2064 monotherapy for at least six months experienced a ≥ 1-grade reduction in collagen fibrosis...
Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial
Partial response seen in three of five patients with advanced non-small cell lung cancer who received GB1211 100 mg plus atezolizumab for at least three...
Why Galecto Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
Gainers
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are worth keeping track of and we're helping with the biggest winners and losers for Wednesday morning!
Galecto reduces workforce by 70%, explores potential strategic alternatives (NASDAQ:GLTO)
Galecto plans to cut 70% of its workforce and explore strategic alternatives, including mergers and divestitures, as it implements a restructuring plan.
Galecto Announces Plans to Explore Strategic Alternatives
BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel...
Galecto to Present at Investor Conferences in September
BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology...
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
Announces next steps for clinical development plan in severe liver diseases...
Galecto Reports Second Quarter Operating and Financial Results
BOSTON, July 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology...
Galecto an outperform at Oppenheimer on fibrosis assets catalysts
Oppenheimer has started Galecto with an outperform rating saying that the biotech's fibrosis candidates have catalysts that could bode well. Read more here.